

---

Charles Darwin University

**Area-under-the-HbA1c-curve above the normal range and the prediction of microvascular outcomes  
an analysis of data from the Diabetes Control and Complications Trial**

Maple-Brown, Louise; Ye, C; Retnakaran, R

*Published in:*  
Diabetic Medicine

*DOI:*  
[10.1111/dme.12004](https://doi.org/10.1111/dme.12004)

Published: 01/01/2013

*Document Version*  
Peer reviewed version

[Link to publication](#)

*Citation for published version (APA):*

Maple-Brown, L., Ye, C., & Retnakaran, R. (2013). Area-under-the-HbA1c-curve above the normal range and the prediction of microvascular outcomes: an analysis of data from the Diabetes Control and Complications Trial. *Diabetic Medicine*, 30(1), 95-99. <https://doi.org/10.1111/dme.12004>

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

"This is the peer reviewed version of the following article: Maple-Brown, L. J., Ye, C. and Retnakaran, R. (2013), Area-under-the-HbA1c-curve above the normal range and the prediction of microvascular outcomes: an analysis of data from the Diabetes Control and Complications Trial. *Diabetic Medicine*, 30: 95–99. doi:10.1111/dme.12004, which has been published in final form at <https://doi.org/10.1111/dme.12004>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving."

Received Date : 25-Apr-2012  
Revised Date : 23-Jul-2012  
Accepted Date : 28-Aug-2012  
Article type : Short Report

**Technical Editor DRH**

**Short Report: Complications**

**Area-under-the-HbA<sub>1c</sub>-curve above the normal range and the prediction of  
microvascular outcomes: an analysis of data from the Diabetes Control and  
Complications Trial**

L. J. Maple-Brown<sup>1,2,3</sup>, C. Ye<sup>1</sup> and R. Retnakaran<sup>1,4</sup>

<sup>1</sup>Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, ON, Canada, <sup>2</sup>Menzies School of Health Research, Charles Darwin University, <sup>3</sup>Division of Medicine, Royal Darwin Hospital, Darwin, NT, Australia and <sup>4</sup>Division of Endocrinology, University of Toronto, Toronto, ON, Canada

*Correspondence to:* Ravi Retnakaran. E-mail: rretnakaran@mtsinai.on.ca

**Running head:** Area-under-the-HbA<sub>1c</sub>-curve in the DCCT • *L. J. Maple-Brown et al.*

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:

10.1111/dme.12004

© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK

## Abstract

**Aims** In the Diabetes Control and Complications Trial, mean updated HbA<sub>1c</sub> accounted for most of the differential risk of microvascular complications between intensive and conventional insulin therapy. We hypothesized, however, that a more precise measure of chronic hyperglycaemic exposure may be the incremental area-under-the-HbA<sub>1c</sub>-curve above the Diabetes Control and Complications Trial-standardized normal range for HbA<sub>1c</sub> (iAUC<sub>HbA1c>norm</sub>).

**Methods** Using the Principal Diabetes Control and Complications Trial data set, we compared the following three measures of chronic glycaemic exposure for their capacity to predict retinopathy, nephropathy and neuropathy during the Diabetes Control and Complications Trial: mean updated HbA<sub>1c</sub>, iAUC<sub>HbA1c>norm</sub>, and total area-under-the-HbA<sub>1c</sub>-curve (tAUC<sub>HbA1c</sub>). For each outcome, models using each of these three glycaemic measures were compared in the following three ways: hazard or odds ratio,  $\chi^2$  statistic, and Akaike information criterion.

**Results** The three glycaemic measures did not differ in their prediction of neuropathy. iAUC<sub>HbA1c>norm</sub> was modestly superior to mean updated HbA<sub>1c</sub> for predicting nephropathy ( $\chi^2$   $P = 0.017$ , Akaike  $P = 0.032$ ). In contrast, for predicting retinopathy, both iAUC<sub>HbA1c>norm</sub> ( $\chi^2$   $P = 0.0005$ , Akaike  $P = 0.0005$ ) and tAUC<sub>HbA1c</sub> ( $\chi^2$   $P = 0.004$ , Akaike  $P = 0.0004$ ) were significantly better than mean updated HbA<sub>1c</sub>. Varying its HbA<sub>1c</sub> threshold incrementally between 37 and 53 mmol/mol (5.5–7.0%), inclusive, did not improve the prediction of retinopathy by iAUC<sub>HbA1c>threshold</sub> beyond that of tAUC<sub>HbA1c</sub>, consistent with the concept of a continuous relationship between glycaemia and retinopathy, with no glycaemic threshold.

**Conclusions** Both iAUC<sub>HbA1c>norm</sub> and tAUC<sub>HbA1c</sub> were superior to mean updated HbA<sub>1c</sub> for predicting retinopathy. Optimal assessment of chronic glycaemic exposure as a determinant of

retinopathic risk may require consideration of both the degree of hyperglycaemia and its duration.

**Abbreviations**  $iAUC_{HbA_{1c}}$ , incremental area-under-the-HbA<sub>1c</sub>-curve;  $iAUC_{HbA_{1c}>norm}$ , incremental area-under-the-HbA<sub>1c</sub>-curve above the normal range for the DCCT-standardized HbA<sub>1c</sub> assay;  $tAUC_{HbA_{1c}}$ , total area-under-the-HbA<sub>1c</sub>-curve; DCCT, Diabetes Control and Complications Trial; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine

## Introduction

The Diabetes Control and Complications Trial (DCCT) study group reported that intensive insulin therapy can reduce the development and progression of retinopathy, nephropathy and neuropathy in Type 1 diabetes, with glycaemic exposure (as determined by mean updated HbA<sub>1c</sub>) explaining virtually all of the difference in risk of these complications between the intensive and conventional therapy groups [1–3]. These data highlight the central importance of chronic exposure to hyperglycaemia as a determinant of microvascular complications in patients with Type 1 diabetes. Although assessed by the mean updated HbA<sub>1c</sub> in the DCCT, we hypothesized that a more precise measure of chronic hyperglycaemic exposure would be the incremental area-under-the-HbA<sub>1c</sub>-curve above the DCCT-standardized normal range for HbA<sub>1c</sub> ( $iAUC_{HbA_{1c}>norm}$ ). Indeed, this measure provides a way of integrating both the degree of glycaemia and the time spent above the normoglycaemic range, and hence could capture the cumulative exposure to hyperglycaemia. As such, by reflecting the presumed key biologic risk determinant relevant to the development of microvascular complications, it may be

a stronger predictor of these outcomes than mean updated HbA<sub>1c</sub>. Thus, we sought to evaluate the predictive capacity of iAUC<sub>HbA<sub>1c</sub>>norm</sub> as a determinant of microvascular complications in the DCCT, as compared with mean updated HbA<sub>1c</sub>.

## Methods

The DCCT has been previously described in detail [4,5]. In brief, 1441 participants with Type 1 diabetes were randomized to intensive or conventional insulin therapy and followed for a mean 6.5 years, with quarterly measurement of HbA<sub>1c</sub> and regular assessment for microvascular complications. Using the publicly available Principal DCCT data set (National Technical Information Service, Alexandria, VA, USA), we evaluated the following three measures of chronic glycaemic exposure: mean updated HbA<sub>1c</sub>, mean iAUC<sub>HbA<sub>1c</sub>>norm</sub> and mean total area-under-the-HbA<sub>1c</sub>-curve (tAUC<sub>HbA<sub>1c</sub></sub>).

These measures were assessed because, while mean updated HbA<sub>1c</sub> will reflect the actual mean value for HbA<sub>1c</sub> over follow-up, it does not account for duration of time spent above a particular glycaemic threshold [such as the upper-limit-of-normal for the DCCT-standardized HbA<sub>1c</sub> assay (IFCC 42 mmol/mol or DCCT 6.0%)]. In contrast, iAUC<sub>HbA<sub>1c</sub>>norm</sub> provides a measure of glycaemic exposure that incorporates not only the degree of glycaemia, but also the time spent above the normal range. To illustrate this difference, consider the hypothetical example of two patients with the following quarterly HbA<sub>1c</sub> measurements: Patient A has measurements of 42 mmol/mol (6.0%), 42 mmol/mol, 42 mmol/mol and 42 mmol/mol, while patient B has measurements of 42 mmol/mol, 46 mmol/mol (6.4%), 38 mmol/mol (5.6%) and

42 mmol/mol. Mean updated HbA<sub>1c</sub> will be the same for both patients, but only iAUC<sub>HbA<sub>1c</sub>>norm</sub> will capture the fact that patient B spent time with HbA<sub>1c</sub> over the normal range. Finally, we also assessed tAUC<sub>HbA<sub>1c</sub></sub>, as it is similar to iAUC<sub>HbA<sub>1c</sub>>norm</sub> but does not assume that the upper-limit-of-normal for the DCCT-standardized assay (IFCC 42 mmol/mol or DCCT 6.0%) is an absolute threshold below which glycaemic exposure does not contribute to microvascular risk.

Mean updated HbA<sub>1c</sub> was calculated as the mean of all quarterly HbA<sub>1c</sub> measures up to the visit under study, computed at 6-monthly intervals [3]. Mean AUC<sub>HbA<sub>1c</sub></sub> was calculated by trapezoidal rule as a mean of the number of visits under study. For example, AUC<sub>HbA<sub>1c</sub></sub> at year 3 (12 visits) was calculated as:

$0.5 \times [H_0 + (2 \times H_1) + (2 \times H_2) + (2 \times H_3) + (2 \times H_4) + (2 \times H_5) + (2 \times H_6) + (2 \times H_7) + (2 \times H_8) + (2 \times H_9) + (2 \times H_{10}) + (2 \times H_{11}) + H_{12}] / 12$ , where H<sub>0</sub> is baseline HbA<sub>1c</sub>, H<sub>1</sub> is first-quarterly visit HbA<sub>1c</sub>, H<sub>2</sub> is second-quarterly visit HbA<sub>1c</sub>, etc. Calculations for each 6-monthly or annual interval included all preceding quarterly HbA<sub>1c</sub> measurements since the start of the DCCT.

For each measure of glycaemic exposure, we determined its predictive capacity for incidence of the following DCCT-defined [3] microvascular outcomes: persistent 3-step change in retinopathy, microalbuminuria and neuropathy. Retinopathy and nephropathy were analysed by time-dependent proportional hazards models and neuropathy by logistic regression model. For each outcome, models using each of the three HbA<sub>1c</sub> measures were compared in three ways: hazard or odds ratio,  $\chi^2$  statistic, and Akaike information criterion (Table 1). For both the  $\chi^2$  and Akaike information criterion statistics, pairwise comparisons were conducted using bootstrap

methods (2000 bootstrap samples were drawn from the original data set with replacement). The pairwise differences of the estimated  $\chi^2$  and Akaike information criterion statistics were obtained for each bootstrap sample. The bootstrap method made it possible to estimate the sampling distribution of the pairwise difference of the  $\chi^2$  or Akaike information criterion statistic. Based on this non-parametric method, and the observed pairwise differences, we calculated bootstrap  $P$ -values to control type I error and determine the significance of pairwise differences. The bootstrap  $P$ -values were estimated by the proportion of those bootstrapped  $\chi^2$  or Akaike values at greater than or equal to the observed pairwise difference from the original data.

Models for the prediction of retinopathy were repeated at different HbA<sub>1c</sub> thresholds between 37 and 53 mmol/mol (5.5–7.0%) for comparison of  $iAUC_{HbA_{1c}>threshold}$  vs.  $tAUC_{HbA_{1c}}$  (Table 2). The purpose of this analysis was to see if there was a particular HbA<sub>1c</sub> threshold where  $iAUC_{HbA_{1c}>threshold}$  was superior to  $tAUC_{HbA_{1c}}$  for predicting retinopathy by both  $\chi^2$  and Akaike information criterion. All statistical analyses were performed using Stata 10.0 (StataCorp., College Station, TX, USA) and SAS 9.2 (SSA Institute, Cary, NC, USA).

## Results

All three HbA<sub>1c</sub> measures (mean updated HbA<sub>1c</sub>,  $tAUC_{HbA_{1c}}$ ,  $iAUC_{HbA_{1c}>norm}$ ) were significantly associated with each microvascular outcome (Table 1). However, their comparative predictive capacities differed for each complication. While the three measures did not differ in their prediction of neuropathy,  $iAUC_{HbA_{1c}>norm}$  (but not  $tAUC_{HbA_{1c}}$ ) was superior to mean updated HbA<sub>1c</sub> for prediction of nephropathy ( $\chi^2$  bootstrap  $P = 0.017$ , Akaike bootstrap  $P = 0.032$ ). In contrast, both  $iAUC_{HbA_{1c}>norm}$  ( $\chi^2$  bootstrap  $P = 0.0005$ , Akaike bootstrap



$P = 0.0005$ ) and  $tAUC_{HbA_{1c}}$  ( $\chi^2$  bootstrap  $P = 0.004$ , Akaike bootstrap  $P = 0.0004$ ) were superior to mean updated  $HbA_{1c}$  for the prediction of retinopathy, with no significant difference between  $iAUC_{HbA_{1c}>norm}$  and  $tAUC_{HbA_{1c}}$ . Varying its  $HbA_{1c}$  threshold above or below 42 mmol/mol (6.0%) from 37–53 mmol/mol (5.5–7.0%) did not improve the prediction of retinopathy by  $iAUC_{HbA_{1c}>threshold}$  beyond that of  $tAUC_{HbA_{1c}}$  (Table 2). Specifically, the  $\chi^2$  statistic did not reveal a significant difference between these two measures at any threshold, although the Akaike information criterion statistic found  $tAUC_{HbA_{1c}}$  to be superior to  $iAUC_{HbA_{1c}>threshold}$  at  $HbA_{1c}$  thresholds  $> 48$  mmol/mol (6.5%). Lastly, after adjustment for covariates (baseline  $HbA_{1c}$ , age, gender, BMI, duration of diabetes, treatment group and baseline value of the outcome variable), both  $iAUC_{HbA_{1c}>norm}$  and  $tAUC_{HbA_{1c}}$  remained superior to mean updated  $HbA_{1c}$  for the prediction of retinopathy but not nephropathy or neuropathy (see also Supporting Information, Table S1).

## Discussion

In this analysis, all three  $HbA_{1c}$  indices yielded comparable hazard or odds ratios for the prediction of each microvascular outcome, and the overall benefits of the  $AUC_{HbA_{1c}}$  measures over mean updated  $HbA_{1c}$  were modest. Furthermore, it is recognized that neither the  $AUC_{HbA_{1c}}$  indices nor mean updated  $HbA_{1c}$  are practical measures for calculation in clinical practice. Instead, however, these indices are more relevant as research tools in clinical studies. Indeed, as shown in this analysis,  $AUC_{HbA_{1c}}$  measures can provide insight on the impact of glycaemic exposure on risk of microvascular complications and, potentially, the biology underlying these relationships. In this context, three key findings emerge from the current data.

Accepted Article

First, the demonstration that both  $iAUC_{HbA_{1c}>norm}$  and  $tAUC_{HbA_{1c}}$  were superior to mean updated  $HbA_{1c}$  for the prediction of retinopathy supports the concept that optimal assessment of chronic glycaemic exposure as a determinant of microvascular risk may require consideration of both the degree of hyperglycaemia and its duration. Interestingly, Orchard and colleagues previously explored this general concept with their construct of  $A_1months$ , defined as the product of  $HbA_{1c}$  above the normal range and months of exposure, as determined from biennial assessment in the Pittsburgh Epidemiology of Diabetes Complications study [6]. While they found that this measure was not a better predictor of microvascular complications than its components (duration and mean  $HbA_{1c}$ ), it should be noted that its calculation from biennial  $HbA_{1c}$  assessments would have rendered  $A_1months$  a less precise measure of chronic glycaemic exposure than the  $AUC_{HbA_{1c}}$  indices obtained from the more frequent  $HbA_{1c}$  measurements in the DCCT. Thus, the  $AUC_{HbA_{1c}}$  measures in the current study may have been better able to demonstrate the predictive capacity of a cumulative glycaemic exposure variable that incorporates both duration and degree of glycaemia.

Secondly, it is noted that  $iAUC_{HbA_{1c}>norm}$  and  $tAUC_{HbA_{1c}}$  were both consistently superior to mean updated  $HbA_{1c}$  for the prediction of retinopathy, but not nephropathy and neuropathy. This difference may relate to methodologic features (e.g. neuropathy was assessed only at 5 years, while retinopathy was assessed every 6 months) or limitations in the measurement of nephropathy and neuropathy outcomes, but also may reflect a comparatively greater influence of glycaemic exposure on risk of retinopathy, as compared with the other outcomes. Thirdly, we did not detect an  $HbA_{1c}$  level above which  $iAUC_{HbA_{1c}}$  surpasses  $tAUC_{HbA_{1c}}$  for predicting retinopathy, consistent with the concept of a continuous relationship between glycaemia and retinopathy, with no glycaemic threshold [3].

Accepted Article

Finally, it should be noted that, although non-glycaemic factors may also be relevant [7], the unmeasured effect of glycaemic exposure in the years prior to the DCCT may have limited the achievable predictive capacity of all three HbA<sub>1c</sub>-based measures obtained during the trial. Thus, iAUC<sub>HbA<sub>1c</sub>>norm</sub> and tAUC<sub>HbA<sub>1c</sub></sub> from the time of diagnosis ultimately warrant study for the evaluation of total cumulative glycaemic exposure as a determinant of microvascular risk in Type 1 diabetes.

### **Competing interests**

Nothing to declare.

### **Acknowledgements**

The authors thank Dr Bernard Zinman (University of Toronto and Leadership Sinai Centre for Diabetes, Toronto, Canada) for advice and helpful discussion. The authors thank DCCT Investigators and participants for their landmark contributions to the understanding of diabetes control and complications. LMB is supported by an Australian National Health and Medical Research Council Early Career Fellowship no. 605837. RR is supported by a Canadian Institutes of Health Research New Investigator award, Canadian Diabetes Association Clinician Scientist incentive funding, and an Ontario Ministry of Research and Innovation Early Researcher Award.

### **References**

1. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; **329**: 977–986.

2. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glyceemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial—revisited. *Diabetes* 2008; **57**: 995–1001.
3. DCCT Research Group. The relationship of glyceemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. *Diabetes* 1995; **44**: 968–983.
4. DCCT Research Group. The Diabetes Control and Complications Trial (DCCT): Design and methodologic considerations for the feasibility phase. *Diabetes* 1986; **35**: 530–545.
5. DCCT Research Group. Diabetes Control and Complications Trial (DCCT). Update. *Diabetes Care* 1990; **13**: 427–433.
6. Orchard TJ, Forrest KY, Ellis D, Becker DJ. Cumulative glyceemic exposure and microvascular complications in insulin-dependent diabetes mellitus. The glyceemic threshold revisited. *Arch Intern Med* 1997; **157**: 1851–1856.
7. Hirsch IB, Brownlee M. Beyond hemoglobin A1c—need for additional markers of risk for diabetic microvascular complications. *J Am Med Assoc* 2010; **303**: 2291–2292.

### Supporting Information

Additional Supporting Information may be found in the online version of this article;

**Table S1.** Comparative performance of each measure of glycaemic exposure for the prediction of microvascular outcomes, adjusted for baseline HbA<sub>1c</sub>, age, gender, BMI, duration of diabetes, treatment group and baseline value of the outcome variable.

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than for missing material) should be directed to the corresponding author for the article.

**Table 1** Comparative performance of each measure of glycaemic exposure for the prediction of microvascular outcomes

	Mean updated HbA <sub>1c</sub>	tAUC <sub>HbA<sub>1c</sub></sub>	iAUC <sub>HbA<sub>1c</sub>&gt;norm</sub>	P-values for pairwise comparisons§		
				Mean updated HbA <sub>1c</sub> vs. tAUC <sub>HbA<sub>1c</sub></sub>	Mean updated HbA <sub>1c</sub> vs. iAUC <sub>HbA<sub>1c</sub>&gt;norm</sub>	tAUC <sub>HbA<sub>1c</sub></sub> vs. iAUC <sub>HbA<sub>1c</sub>&gt;norm</sub>
Retinopathy* (n = 1440)						
Hazard ratio (95% CI)	1.64 (1.52–1.77)	1.69 (1.57–1.83)	1.68 (1.56–1.82)	N/A	N/A	N/A
$\chi^2$ †	161.65	174.54	171.71	0.004	0.0005	0.170
Akaike information criterion‡	2847.83	2837.39	2839.22	0.004	0.0005	0.264
Nephropathy* (n = 1365)						
Hazard ratio (95% CI)	1.31 (1.22–1.41)	1.33 (1.23–1.43)	1.33 (1.23–1.44)	N/A	N/A	N/A
$\chi^2$ †	50.18	52.18	53.21	0.068	0.017	0.039
Akaike information criterion‡	3517.83	3516.15	3515.45	0.076	0.032	0.077
Neuropathy* (n = 1161)						
Odds ratio (95% CI)	1.53 (1.34–1.74)	1.53 (1.35–1.75)	1.54 (1.35–1.75)	N/A	N/A	N/A
$\chi^2$ †	41.91	42.05	42.17	0.368	0.328	0.256
Akaike information criterion‡	662.35	662.26	662.31	0.412	0.474	0.424

\*Retinopathy was defined as persistent 3-step change from baseline, graded according to the Early Treatment Diabetic Retinopathy Study scale. Nephropathy was defined as urine albumin excretion rate  $\geq 40$  mg/24 h. Neuropathy was defined on clinical examination at 5 years with concurrent/prior abnormalities in nerve conduction or autonomic nervous system testing. Retinopathy and nephropathy were analysed by time-dependent proportional hazards models as they were assessed regularly during the DCCT. Neuropathy was analysed by logistic regression model because it was assessed only at 5 years. Patients with urine albumin excretion rate  $> 40$  mg/24 h at baseline were excluded from nephropathy models and those with neuropathy at baseline were excluded from neuropathy models.

†A larger  $\chi^2$  statistic indicates stronger evidence of an increasing trend over time in the effect of a measure of glycaemic exposure on the hazard or risk of an outcome.

‡The Akaike information criterion offers a measure of the information lost when a statistical model is used to describe reality. Thus, in this study, given a set of models using three measures of glycaemic exposure for each outcome, the preferred model is the one with the minimum Akaike information criterion value, as least information is lost.

§The pairwise comparisons were conducted using bootstrap methods (2000 bootstrap samples were drawn from the original data set with replacement). The pairwise differences of the estimated  $\chi^2$  and Akaike information criterion statistics were obtained for each bootstrap sample. The bootstrap *P*-values were estimated by the proportion of those bootstrapped  $\chi^2$  or Akaike values at greater than or equal to the observed pairwise difference from the original data.

iAUC<sub>HbA<sub>1c</sub>>norm</sub>, incremental area-under-the-HbA<sub>1c</sub>-curve above the normal range for the DCCT-standardized HbA<sub>1c</sub> assay;

tAUC<sub>HbA<sub>1c</sub></sub>, total area-under-the-HbA<sub>1c</sub>-curve; N/A, not applicable.

**Table 2** Comparison of iAUC<sub>HbA<sub>1c</sub>>threshold</sub> and tAUC<sub>HbA<sub>1c</sub></sub> for the prediction of the risk of retinopathy, for sequential incremental HbA<sub>1c</sub> thresholds (T) from 37 to 53 mmol/mol (5.5 to 7.0%) inclusive

HbA <sub>1c</sub> threshold (T)		Hazard ratio	$\chi^2$ -test		Akaike information criterion	
IFCC (mmol/mol)	DCCT (%)		Value	<i>P</i> -value for iAUC <sub>HbA<sub>1c</sub>&gt;T</sub> vs. tAUC <sub>HbA<sub>1c</sub></sub>	Value	<i>P</i> -value for iAUC <sub>HbA<sub>1c</sub>&gt;T</sub> vs. tAUC <sub>HbA<sub>1c</sub></sub>
37	5.5	1.682	171.50	0.166	2838.74	0.316
38	5.6	1.682	171.55	0.169	2838.77	0.313
39	5.7	1.682	171.58	0.171	2838.85	0.293
40	5.8	1.683	171.64	0.175	2838.93	0.294
41	5.9	1.683	171.62	0.163	2839.05	0.278
43	6.1	1.684	171.81	0.180	2839.44	0.240
44	6.2	1.686	171.90	0.190	2839.74	0.205
45	6.3	1.687	171.95	0.200	2840.15	0.158
46	6.4	1.689	171.98	0.204	2840.70	0.109
48	6.5	1.690	171.94	0.202	2841.36	0.078
49	6.6	1.693	171.96	0.211	2842.08	0.047
50	6.7	1.696	172.05	0.225	2842.86	0.024
51	6.8	1.700	172.06	0.237	2843.76	0.014
52	6.9	1.705	172.29	0.264	2844.59	0.008
53	7.0	1.710	172.40	0.281	2845.56	0.005

iAUC<sub>HbA<sub>1c</sub></sub>, incremental area-under-the-HbA<sub>1c</sub>-curve; tAUC<sub>HbA<sub>1c</sub></sub>, total area-under-the-HbA<sub>1c</sub>-curve; DCCT, Diabetes Control and Complications Trial; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine.